Liver Disease Treatment Market is expected to reach US$ 40.94 billion by 2033 | Major key players - AbbVie, Gilead Sciences, Inc, Astellas Pharma Inc.

Market Size and Forecast:

The Global Liver Disease Treatment Market size reached US$ 21.36 billion with rise of US$ 22.70 billion in 2024 is expected to reach US$ 40.94 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033. The Market growth is driven by the rising prevalence of liver disorders such as hepatitis and fatty liver disease, coupled with increasing adoption of advanced therapeutic options. According to DataM Intelligence

To Download a Free Sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/liver-disease-treatment-market?sz

The Liver Disease Treatment Market refers to the global industry focused on developing and providing therapeutic solutions for liver disorders such as hepatitis, cirrhosis, fatty liver disease, and liver cancer. It includes pharmaceuticals, biologics, and regenerative therapies aimed at improving liver function, preventing disease progression, and enhancing patient outcomes through advanced diagnostics and innovative treatment approaches.

Industry Recent Developments: United States

✅ September 2025: The FDA approved a new RNA-based therapy for non-alcoholic steatohepatitis (NASH), marking a significant advancement in liver disease treatment.

✅ August 2025: Major clinical trials advanced for innovative antiviral and hepatoprotective treatments targeting hepatitis and liver fibrosis.

✅ August 2025: Increasing investment in R&D for novel liver therapeutics, including biologics and regenerative medicine, is driving market growth.

Industry Recent Developments: Japan

✅ September 2025: Japan's Ministry of Health, Labour and Welfare approved Bylvay (odevixibat) for treating pruritus associated with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease.

✅ September 2025: Continued growth in Hepatitis C treatments driven by advancements in direct-acting antiviral therapies and government programs aiming for Hepatitis C eradication.

✅ August 2025: Rising prevalence of non-alcoholic fatty liver disease (NAFLD) and liver cancer due to aging population and lifestyle changes, with expanding applications of personalized medicine and combination therapies.

Get Customization in the report as per your requirements + Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/liver-disease-treatment-market?sz

FDA Approvals / Label expansions (2025):

✅ Glecaprevir/pibrentasvir (Mavyret) - label expansion to treat acute HCV (8-week regimen) - June 11, 2025. This makes Mavyret the first oral DAA approved for both acute and chronic HCV in patients ≥3 years.

✅ Semaglutide (Wegovy) - FDA approval for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis - mid August 2025 (FDA announcement in Aug 2025). Landmark because it's the first GLP-1 with an approved MASH indication at this stage.

Regulatory Milestones & Notable regulatory actions (2025):

✅ EMA qualification - AIM-NASH (AI tool) - Mar 20, 2025: EMA issued a Qualification Opinion for an AI tool (AIM-NASH) to assist MASH biopsy reading in trials (important for trial standardization).

✅ EMA recommendation / positive CHMP activity - resmetirom (Rezdiffra) for MASH/fibrosis - June 2025: CHMP/EMA activity around resmetirom (trade name Rezdiffra) as a candidate for MASH/liver-fibrosis indications appeared in mid-2025.

✅ FDA regulatory pathway developments for MASH/NASH - 2025 saw FDA discussion/acceptance of surrogate-endpoint proposals and heightened agency engagement on acceptable endpoints for MASH outcomes (regulatory guidance momentum).

✅ IND/clearance for novel approaches (example) - Mar 17, 2025: Precision Bio announced clearance to begin a first-in-human trial for an in-vivo gene-editing program for chronic hepatitis B (PBGENE-HBV) - notable regulatory milestone for HBV gene-editing approaches. i

Major Mergers, Acquisitions (2025):

✅ Roche → 89bio - agreement to acquire 89bio (FGF21 program for MASH) - Sept 18, 2025 (deal announced / tender process begun). This expands Roche's metabolic/hepatology pipeline.

✅ Novo Nordisk → Akero Therapeutics - definitive agreement to acquire Akero (efruxifermin, FGF21 candidate for MASH) - Oct 9, 2025 (announcement). Big strategic push to add MASH assets alongside GLP-1 portfolio.

✅ GSK completes acquisition of efimosfermin asset - July 7, 2025: GSK closed a deal to acquire efimosfermin (a late-stage candidate targeting steatotic liver disease).

✅ Bausch Health completes acquisition of DURECT - Sept 11, 2025: deal adds larsucosterol (alcohol-associated hepatitis candidate; Breakthrough designation history) into Bausch's hepatology pipeline.

Major Key Players:

AbbVie
Gilead Sciences, Inc
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb
Astellas Pharma Inc.
Intercept Pharmaceuticals
Madrigal Pharmaceuticals
Akero Therapeutics.

Segments Covered in the Liver Disease Treatment Market:

By Treatment Type: Antiviral Drugs, Immunosuppressants, Vaccines, Immunosuppressants, Corticosteroids, Targeted Therapies, Chemotherapy Drugs, Biologics, Others.

By Disease Type: Hepatitis, Alcohol-related liver disease, Haemochromatosis, Primary biliary cholangitis, Others.

By Route of Administration: Oral, Injectable.

By End User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis for Liver Disease Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=liver-disease-treatment-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Liver Disease Treatment market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Liver Disease Treatment Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Liver Disease Treatment market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Liver Disease Treatment Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Liver Disease Treatment market?

➠ Who are the global key manufacturers of the Liver Disease Treatment Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Liver Disease Treatment market opportunities and threats faced by the vendors in the global Liver Disease Treatment Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Liver Disease Treatment market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.